|
Published by: Decision Resources
Published: Nov. 2, 2009 - 37 Pages
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Changing Opportunities
- Spectrum’s Coverage of Central Nervous System Diseases
- Neurology Industry: Market Size and Major Players
- Top Players
- Changing Neurology Franchises
- Impact of Patent Expiry
- Largest Deals and Dealmakers
- Deal Volume
- Largest Deals
- Most Prolifi c Dealmakers
- GlaxoSmithKline
- H. Lundbeck
- Elan
- Neurology-Focused Foundations
- Big Pharma Collaboration and Pitfalls
- Disease and Technology Deals
- Deals By Disease Category
- Deals by Technology
- Antibody Deals
- Recombinant Protein Deals
- Therapeutic Vaccine Deals
- Staying Alive—or Not
- Liquidation
- Reverse Merger
- Consolidation
- Mergers and Acquisitions
- New Genes and Pathways Suggest the Possibility of New Targeted Therapies
- A Potential New Mechanism of Action Involving Mitochondria
- New Genes and Pathway Discoveries
- Disruptive Technologies
- Industry Outlook
- Expert Commentary
- Potential New Mechanism of Action for the Treatment of Neurodegenerative Diseases
- David Hung, M.D., President and CEO, Medivation, Inc.
- Tables
- 1. Neurological Diseases: Most Prolifi c Corporate Dealmakers, 2007-2009
- 2. Neurological Diseases: Most Prolifi c Nonprofi t Dealmakers, 2007-2009
- Figures
- 1. Central Nervous System Diseases: Projected Worldwide Sales, 2008-2015
- 2. Neurological Diseases: Top 25 Companies Based on Worldwide Neurology Sales, 2008 and 2013
- 3. Neurological Diseases: Market Share of Top Companies, 2008 and 2013
- 4. Neurological Diseases: Deal Volume Based on Potential Deal Size, 2007-2009
- 5. Neurological Diseases: The Largest Deals, 2007-2009
- 6. Neurological Diseases: Most Prolifi c Dealmakers, 2007-2009
- 7. Neurological Diseases: Deals By Disease Category, 2007-2009
- 8. Neurological Diseases: Deals by Technology, 2007-2009
- 9. Neurological Diseases: Mergers and Acquisitions, 2007-2009
AbstractThe plethora of recent reports of new genes and pathways linked to neurological diseases shows that the underlying
causes of these diseases are far from certain; as a result, therapeutic strategies in effect today may soon
be superseded by new approaches. The key to future success in this therapy area is a better understanding of
the underlying biomarkers, genes, and disease pathways that lead to disease. Pharma companies have scoured
the ranks of available drug targets, technologies, and innovation in neurological diseases and have executed a
plethora of acquisitions and deals. In this report, we categorize more than 300 deals in the neurological disease
industry for a 32-month period including 2007, 2008, and the first eight months of 2009. We assess the neurology
market and its major players as well as analyze the deals that companies are executing and the business
strategies they are deploying to gain future success.
Questions Answered in This Report
- Decision Resources Pharmaview analysts forecast that the neurology market will grow to $45.2 billion in
2013. Which pharma companies will be the major players in 2013? What will account for much of the
fl ux that will be seen in neurology markets from 2008 to 2013?
- Analyzing deals opens up a window to a company's business strategies. What do the 340 deals in the neurology
industry for 2007, 2008, and the first eight months of 2009 say about pharma companies' strategies
in this therapy area? What targets were licensed or optioned? What were the largest deals and who
were the most prolific dealmakers? What merger and acquisition strategies were in play?
- Complications can arise when multiple parties hold rights to the same product and companies get
overzealous in their partnering activities? What almost derailed Elan's Tysabri collaboration with
Biogen Idec? Why are Johnson & Johnson and Pfizer now partners on an immunotherapy
program for AD?
- Too many small biotechs have too few products of unknown quality to entice investors in a tight
money market to invest. How big of a concern is bankruptcy or liquidation for small neurology
companies? Which companies have chosen to survive by reverse merger or consolidation?
- Companies are scouring early-stage technology opportunities for breakthrough technologies and
innovative product candidates. Why are disease-specific disease foundations so important? What
disruptive therapies are in development? What technologies are hot?
- Researchers must gain a better understanding of disease pathways because interrupting these pathways
is the basis of targeted therapeutic intervention. What recent gene discoveries and disease
pathways have been discovered? What new therapeutic approaches might supersede existing
therapies in development?
Scope
- Expert commentary: Mechanism of action, mitochondria, misfolded proteins, disease pathogenesis,
new therapeutic approach, Medivation, Dimebon, Huntington Study Group.
- Diseases: Amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), epilepsy, Huntington's
disease (HD), insomnia, migraine, multiple sclerosis (MS), Parkinson's disease (PD), restless legs
syndrome (RLS), stroke.
- Therapy area: Market size, top 25 companies, blockbusters, market share, changing franchises,
major products, patent expiry, companies gaining and losing the most sales, new genes, new targets
and disease pathways, new therapeutic approaches.
- Dealmaking: Analysis of more than 300 deals, deal volume, mega-deals valued at more than $1
billion, deals valued at more than $400 million, most-prolific dealmakers, disease-focused nonprofit
organizations, dealmaking pitfalls, Big Pharma collaboration, change of control licensing provisions,
disease deals, technology deals.
- Business strategies: Collaborations, codevelopment, co-commercialization, copromotion, strategic
alliances, inlicensing, mergers and acquisitions (M&As), divestment, product acquisitions, patent litigation
settlements, marketing agreements, marketed product portfolio acquisitions, brand expansion,
international expansion, emerging markets, royalty buyouts, manufacturing agreements, options,
mega-mergers, targeted acquisitions, activist investors, liquidation, reverse mergers, consolidation,
strengthening franchises.
- Targets: Neuronal nicotinic receptors, orexin receptor, beta-amyloid, neuronal potassium channel
openers, autophagy pathway targets, alpha-synuclein, neural glial cell markers, selective adhesion
molecules, granulocyte-macrophage colony-stimulating factor, fibroblast growth factor receptor 5,
interferon-beta, human alpha-fetoprotein, fibroblast growth factor-2, toll-like receptor 9, myelin basic
protein, N-type calcium channels, T-type calcium channels, M1 selective muscarinic agonists, Rasrelated
guanosine triphosphate-binding proteins, huntingtin, chloride-gated ion channels, presenilin-1
and -2.
- Technologies: Immunotherapy, therapeutic vaccines, biologics, biosimilars, stem cell therapy, predictive
screening, cell models, new formulations, disease-modifying therapies, peptides, gene therapy,
RNA interference, recombinant proteins, biomarkers, glutathione-coated liposomes, nanobodies, Fcfusion
proteins, monoclonal antibodies, knock out mice, acetylcholinesterase.
Please note, the PDF e-mail from publisher version of this report is for a global site license.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
